This study was undertaken in 2 parts to investigate the relationship between body size and insulin resistance during treatment with valproic acid in children. The cross-sectional part revealed differences in terms of body size and homeostasis model assessment of insulin resistance, which were higher in the group on medication. The longitudinal part showed a major increase in body size and insulin resistance during the first year of therapy. There was a subsequent decrease in insulin resistance in association with the rise of body size, however with a trend to level off. These results might be helpful to enhance the knowledge of valproic acid action on both insulin resistance and weight gain, allowing to plan appropriate approach for the prevention of the consequences of the treatment with valproic acid.
Greenwood RSAdverse effects of antiepileptic drugs. Epilepsia. 2000;41(suppl 2):S42-S52.
2.
Egger J., Brett EMEffects of sodium valproate in 100 children with special reference to weight . Br Med J (Clin Res Ed). 1981; 283(6291):577-581.
3.
Novak GP, Maytal J., Alshansky A., Eviatar L., Sy-Kho R., Siddique Q.Risk of excessive weight gain in epileptic children treated with valproate . J Child Neurol. 1999;14(8):490-495.
4.
Espinosa PS, Salazar JC, Yu L., Mendiondo MS, Robertson WC, Baumann RJLack of valproic acid-associated weight gain in prepubertal children. Pediatr Neurol. 2008;39(3):177-180.
5.
Rauchenzauner M., Haberlandt E., Scholl-Burgi S., et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children . Epilepsy Res. 2008; 80(2-3):142-149.
6.
Pylvanen V., Pakarinen A., Knip M., Isojarvi J.Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8(3):643-648.
7.
Isojarvi JI, Laatikainen TJ, Knip M., Pakarinen AJ, Juntunen KT, Myllylä VVObesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579-584.
8.
Aydin K., Serdaroglu A., Okuyaz C., Bideci A., Gucuyener K.Serum insulin, leptin and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol. 2005;20(10):848-851.
Verrotti A. , la Torre R., Trotta D., Mohn A., Chiarelli F.Valproate-induced insulin resistance and obesity in children. Horm Res. 2009;71(3):125-131.
11.
Luef GJ, Lechleitner M., Bauer G., Trinka E., Hengster P.Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res. 2003;55(1-2): 53-58.
12.
Verrotti A., Basciani F., Morresi S., de Martino M., Morgese G., Chiarelli F.Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology. 1999;53(1): 230-232.
13.
Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics. 2000;105(3 pt 1):671-680.
14.
Weiss R., Caprio S.The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab. 2005;19(3): 405-419.
15.
Engel J. Jr.ILAE classification of epilepsy syndromes. Epilepsy Res. 2006;70(suppl 1):S5-S10.
16.
World Health Organization.Part 1: Diagnosis and Classification of Diabetes Mellitus. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications . Geneva, Switzerland: WHO/NCD/NCS/99.2; 1999.
17.
Matthews DR , Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RCHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419.
18.
CDC National Center for Health Statistics, Health E-Stat.NHANES Data on the Prevalence of Overweight Among Children and Adolescents. United States; 2003- 2004.
19.
Moreno LA, Rodrıguez G., Guillen J., Rabanaque MJ, León JF, Ariño A.Anthropometric measurements in both sides of the body in the assessment of nutritional status in prepubertal children. Eur J Clin Nutr . 2002;56(12):1208-1215.
20.
Caksen H., Deda G., Berberoglu M.Does long-term use of valproate cause weight gain in prepubertal epileptic children? Int J Neurosci. 2002;112(10):1183-1189.
21.
Knowler WC, Barrett-Connor E., Fowler SE, et al., for the Diabetes Prevention Program Research Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
22.
Demir E., Aysun S.Weight gain associated with valproate in childhood. Pediatr Neurol. 2000;22(5):361-364.
23.
Pylvanen V. , Pakarinen A., Knip M., Isojarvi J.Characterization of insulin secretion in valproate treated patients with epilepsy. Epilepsia. 2006;47(9):1460-1464.
24.
Vorum H., Gram L., Honore B.Valproate and palmitate binding to serum albumin in valproate-treated patients . Relation to obesity. Epilepsy Res. 1993;16(1):55-64.
25.
Ferranini E. , Barrett EJ, Bevilacqua S., De Fronzo RAEffects of free fatty acids on glucose production and utilization in man. J Clin Invest. 1983 ;72:1268-1277.
26.
Grosso S., Mostardini R., Piccini B., Balestri P.Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother.2009;43(1):45-50.
